info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
United States Flag  US: +1-315-636-4233    United Kingdom Flag  UK: +44-162-237-0614    Indian Flag  IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Press Releases » Renal denervation market size will be worth 4743.13 million U.S. dollars by 2030.

Renal denervation market size will be worth 4743.13 million U.S. dollars by 2030.


Published Date: Apr-2022 | Report Format:Electronic (PDF)

The report "Renal denervation devices" market is segmented By Product (Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, and others), By Technology (radiofrequency, ultrasound, micro-infusion, and others), By end-user (hospitals, clinics, ambulatory surgical centres, and others), and By Region (North America, Europe, Asia Pacific (APAC), and Rest of the world) – Global forecast to 2030. By 2030, the global Renal denervation market size will reach 4743.13 million U.S. dollars with a significant growing CAGR of 40.7%.

  

To know more about the report, Click on the link :-  https://www.strategicmarketresearch.com/market-report/renal-denervation-market

 

KEY FACTORS AUGMENTING THE MARKET GROWTH 

The increasing prevalence of hypertension and newer technologies developed to treat resistant hypertension globally are the key reasons for the increasing market size of renal denervation devices. Globally, according to the reports suggested by WHO, 2021, the number of people affected by hypertension aged between 30 years and 79 years is approximately 1.28 billion. Thus, increasing demand for treating hypertension is the driving factor for the growth of the renal denervation market. 

 

By Product "Symplicity" segment held the highest share in 2020 

Based on product, the renal denervation market is segmented into Symplicity, Vessix (V2), EnligHTN, Paradise, Iberis, and others. In 2020, the Symplicity segment will hold the largest market share with a decent CAGR. This segment is expected to widen its market share in the future. 

 

By Technology "radiofrequency" segment held the highest share in 2020 

The renal denervation market is divided into radiofrequency, ultrasound, micro-infusion, and others based on Technology. Currently, radiofrequency is enjoying the largest market share with a growing CAGR throughout the forecasted period. The ease of using radiofrequency Technology to reduce hypertension is the key reason behind this segment's revenues growth.  

 

By region "Europe" segment held the highest share in 2020 

By region, the renal denervation market is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the world. In 2020, Europe will have the largest market share while Asia Pacific will grow with the highest CAGR during the forecasted period. In England, more than one in four adults are affected by high blood pressure as per the data published by Public Health England. The percentage of men with hypertension increased from 28 percent to 30 percent from 2017 to 2018, & rates for women rose by 25% to 26%, according to the NHS Digital data collected through the 2019 Health Survey for England. Lack of exercise, excessive alcohol consumption, consumption of fast food, and smoking, which are causing lifestyle changes are the increased prevalence of hypertension. 

Europe has the highest number of CE approval for renal denervation devices. Thus, major factors contributing to the market's growing revenue are an investment in R&D and new product innovations.  

 

Recent Developments: -  

  • On 6th October 2021, Paradise Ultrasound Renal Denervation System (the "Paradise System") was developed by ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., will be available in Germany for treating hypertension. Heart Center Leipzig and Saarland University Hospital, Homburg/Saar are the first hospitals to treat hypertension using the Paradise system. 
  • In March 2020, Medtronic PLC declared that the first-ever clinical data from the SPYRAL HTN-OFF MED Pivotal Trial. American College of Cardiology, together with the World Congress of Cardiology Scientific, presented the study.  

Choose License Type



$4485
$6449
$8339
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: (+1) 315-636-4233
  • UK: (+44) 1622-370-614
  • IN: (+91) 826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved